Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Origin opens new facility in Alderley Park

Plans to support UK pharma start-ups

- PMLiVE

Pharma ranks bottom in Gallup poll of industry reputation

US opioid epidemic and medicine pricing to blame

- PMLiVE

Boehringer bolsters KRAS push with $720m Lupin deal

Signs of progress in the field are emerging

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

Indegene acquires DT Associates

Provides end-to-end enterprise solution for customer excellence – from consulting to operations

Building the Lucid Group Brand

Dennis O'Brien, Lucid Group CEO, discusses how they will grow the organisation and develop the Lucid Group brand over the next twelve years.

Lucid Group Communications Limited

- PMLiVE

ALK-Abello debuts its birch pollen allergy therapy in Germany

Key market for the new product

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

TMC’s full data for inclisiran impresses at ESC

Marketing applications expected before end of year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links